Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Current Perspectives in Prostate Cancer Vaccines

Author(s): Philip M. Arlen and James L. Gulley

Volume 9, Issue 10, 2009

Page: [1052 - 1057] Pages: 6

DOI: 10.2174/187152009789735062

Price: $65

Abstract

The use of vaccines as a potential therapeutic modality for the treatment of cancer has been extensively studied. Recent advances include identification and characterization of tumor-associated antigens, novel vaccine delivery systems, and the combination of vaccines with immune stimulants and other therapeutic modalities. Immunotherapy as a modality for treatment of prostate cancer has received significant attention. There are several characteristics of prostate cancer that make it an ideal target for immunotherapy. Prostate cancers relative indolence allows sufficient time to generate immune responses, which may take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal vital tissue. This review focuses on promising new vaccines and novel perspectives in the treatment of prostate cancer.

Keywords: Prostate cancer, immunotherapy, vaccine, cancer vaccine, clinical protocols, tumor-associated antigens


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy